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Lipid profile alterations have been observed in patients with coronavirus disease 2019
(COVID-19) in relation to disease severity and mortality. We conducted a systematic
review and meta-analysis with meta-regression of studies reporting total, HDL, and
LDL-cholesterol, and triglyceride concentrations in hospitalized patients with COVID-
19. We searched PubMed, Web of Science and Scopus, between January 2020 and
January 2021, for studies describing lipid concentrations, COVID-19 severity, and survival
status (PROSPERO registration number: CRD42021253401). Twenty-two studies in
10,122 COVID-19 patients were included in the meta-analysis. Pooled results showed
that hospitalized patients with severe disease or non-survivor status had significantly
lower total cholesterol (standardized mean difference, SMD = −0.29, 95% CI −0.41
to −0.16, p < 0.001), LDL-cholesterol (SMD = −0.30, 95% CI −0.41 to −0.18, p
< 0.001), and HDL-cholesterol (SMD = −0.44, 95% CI −0.62 to −0.26, p < 0.001),
but not triglyceride (SMD = 0.04, 95% CI −0.10 to −0.19, p = 0.57), concentrations
compared to patients with milder disease or survivor status during follow up. Between-
study heterogeneity was large-to-extreme. In sensitivity analysis, the effect size of
different lipid fractions was not affected when each study was in turn removed. The
Begg’s and Egger’s t-tests did not show evidence of publication bias, except for
studies investigating LDL-cholesterol. In meta-regression, significant associations were
observed between the SMD of LDL-cholesterol and age and hypertension, and between
the SMD of triglycerides and study endpoint and aspartate aminotransferase. In our
systematic review and meta-analysis, lower total, HDL, and LDL-cholesterol, but not
triglyceride, concentrations were significantly associated with COVID-19 severity and
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mortality. Cholesterol concentrations might be useful, in combination with other clinical
and demographic variables, for risk stratification and monitoring in this group.
Systematic Review Registration: PROSPERO registration number:
CRD42021253401.
Keywords: cholesterol, triglycerides, COVID-19, disease severity, mortality
INTRODUCTION
Since the start of the coronavirus disease 2019 (COVID-
19) pandemic significant advances have been made in the
identification of specific patient characteristics that are associated
with different disease severity and clinical outcomes. For
example, pre-existing comorbidities such as hypertension,
obesity and diabetes, clinical parameters such as hypoxia and CT-
chest imaging findings, and circulating markers of inflammation,
nutrition, hemostasis, and single organ function, have been
investigated in observational studies in COVID-19 patients in
order to develop and validate scoring tools for risk stratification
and monitoring (1, 2). However, the continuing pressures
on health care systems and the unpredictable progression
of the pandemic, with new variants of the causative agent,
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), being discovered, additional efforts are required to further
improve the performance of existing predictive tools (3).
There is increasing evidence of significant alterations in lipid
profile, particularly total cholesterol, LDL-cholesterol, and HDL-
cholesterol concentrations in hospitalized patients with COVID-
19. While increasing concentrations of cholesterol in the cell
membrane have been reported to increase the binding activity
of SARS-CoV-2, facilitating membrane fusion and the successful
entry of the virus to the host (4, 5), clinical studies have
shown acute reductions in plasma/serum concentrations of total
cholesterol, LDL-cholesterol, and HDL-cholesterol in patients
with COVID-19. Notably, the magnitude of this reduction seems
to be proportional to the severity of the disease and might
therefore assist with early risk stratification and clinical decisions
(5, 6). By contrast, studies investigating the concentration
of triglycerides in COVID-19 patients with different severity
have reported variable results (6, 7). In order to capture
and interpret the available evidence regarding the relationship
between COVID-19 and lipid profile, we conducted a systematic
review and meta-analysis of studies reporting plasma/serum
concentrations of total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides in hospitalized COVID-19 patients
with different disease severity and clinical outcomes, particularly
survival status during follow up. We hypothesized that COVID-
19 patients with severe disease and/or not surviving during
follow-up had lower plasma/serum concentrations of total
cholesterol, LDL-cholesterol, and HDL-cholesterol, but not
triglyceride, concentrations, when compared to patients with
mild disease or favorable outcomes. A meta-regression analysis
was also conducted to identify associations between the between-
group total cholesterol, LDL-cholesterol, HDL-cholesterol, and
triglyceride effect size and pre-defined biologically and clinically
plausible variables.
MATERIALS AND METHODS
Search Strategy, Eligibility Criteria, and
Study Selection
A systematic literature search was conducted in the electronic
databases PubMed, Web of Science and Scopus, from January
2020 to January 2021, using the following terms and their
combination: “cholesterol” or “LDL” or “low-density lipoprotein”
or “HDL” or “high-density lipoprotein” or “triglycerides” and
“COVID-19” or “Coronavirus disease-2019” (PROSPERO
registration number: CRD42021253401). Abstracts were
screened independently by two investigators. If relevant, the full
text of the articles were independently reviewed. The references
of the retrieved articles were also reviewed to identify additional
studies. Eligibility criteria included (i) assessment of total
cholesterol and/or LDL-cholesterol and/or HDL-cholesterol
and/or triglyceride concentrations in COVID-19 patients; (ii)
investigation of COVID-19 patients with different disease
severity, based on current clinical guidelines or admission to
the Intensive Care Unit (ICU), or survival status, (iii) adult
patients, (iv) ≥10 subjects, (v) English language, and (vi)
full-text available. The references of the retrieved articles and
reviews were also searched to identify additional studies. Any
disagreement between the reviewers was resolved by a third
investigator. We used the Newcastle-Ottawa Scale (NOS) to
assess study quality, with a score ≥6 indicating high quality (8).
Statistical Analysis
Standardized mean differences (SMD) were used to build forest
plots of continuous data and to evaluate differences in total
cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride
concentrations between COVID-19 patients with low vs. high
severity or survivor vs. non-survivor status. When necessary,
the mean and standard deviation values were extrapolated from
the median and IQR values, as previously reported (9). The Q-
statistic was used to assess the heterogeneity of the SMD across
studies (the significance level was set at p < 0.10). Inconsistency
across studies was evaluated using the I2 statistic where I2 <25%
indicated no heterogeneity, I2 between 25 and 50% moderate
heterogeneity, I2 between 50 and 75% large heterogeneity, and I2
> 75% extreme heterogeneity) (10, 11). A random-effects model
was used, in presence of significant heterogeneity, to calculate
the pooled SMD and the corresponding 95% confidence intervals
(CIs). We also conducted sensitivity analyses to evaluate the
influence of each individual study on the overall effect size with
the leave-one-out method (12). The presence of publication bias
was assessed by means of the Begg’s adjusted rank correlation
t-test and the Egger’s regression asymmetry t-test at the p
< 0.05 level of significance (13, 14). We also performed the
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FIGURE 1 | Flow chart of study selection.
Duval and Tweedie “trim and fill” procedure to further test and
correct the possible effect of publication bias (15). This method
recalculates a pooled SMD by extrapolating and incorporating
the hypothetical missing studies, to increase the observed data
so that the funnel plot is more symmetric. To explore possible
contributors to the between-study variance, we investigated
in meta-regression analysis the associations between the SMD
and the following parameters: age, gender, specific endpoints
(severity, ICU admission, or surviving status), study design
(retrospective or prospective), white blood cell count (WBC),
C-reactive protein (CRP), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), albumin, D-dimer, creatinine,
diabetes, hypertension, and cardiovascular disease. Statistical
analyses were performed using Stata 14 (STATA Corp., College
Station, TX, USA). Our study was fully compliant with the




A flow chart describing the screening process is presented in
Figure 1. We initially identified 2,121 studies. A total of 2,096
studies were excluded after the first screening because they were
either duplicates or irrelevant. After a full-text review of the
remaining 25 articles, three were further excluded because they
either did not provide the required information or did not meet
the inclusion criteria. Thus, 22 studies were included in the
meta-analysis (6, 7, 17–36).
Total Cholesterol
Eighteen studies assessed total cholesterol concentrations in
4,562 COVID-19 patients, 3,179 (46% males, mean age 56 years)
with low severity or survivor status and 1,383 (59% males, mean
age 64 years) with high severity or non-survivor status during
follow up (Table 1) (6, 7, 17, 18, 20, 21, 23–26, 28–30, 32–36).
All studies were conducted in China, except one, performed
in France (30). Two studies were prospective (29, 30), whilst
the remaining 16 were retrospective (6, 7, 17, 18, 20, 21, 23–
26, 28, 32–36). Endpoints included disease severity based on
current clinical guidelines in 13 studies (6, 7, 17, 21, 23, 25, 26,
28, 29, 32–34, 36), ICU admission in two (24, 35), and survival
status in three (18, 20, 30). The overall standardized mean
difference in total cholesterol concentrations between COVID-
19 patients with low vs. high severity or survivor vs. non-
survivor status is shown in Figure 2. In 15 studies, patients with
high severity or non-survivor status had lower total cholesterol
concentrations when compared to those with low severity or
survivor status (mean difference range, −0.71 to −0.03) (6, 7,
17, 18, 20, 24, 26, 28–30, 32–36), although the difference was
not statistically significant in seven studies (7, 17, 24, 30, 32–
34). By contrast, in the remaining three studies (21, 23, 25),
total cholesterol concentrations were lower in patients with
low severity or survivor status (mean difference range, 0.02 to
0.30), even if the difference was not statistically significant. The
pooled results showed that total cholesterol concentrations were
significantly lower in patients with high severity or non-survivor
status (SMD −0.29, 95% CI −0.41 to −0.16, p < 0.001), with
large heterogeneity between studies (I2 = 66.4%, p < 0.001). In
sensitivity analysis, the corresponding pooled SMD values were
not altered when each study was in turn omitted (effect size
ranged between −0.31 and −0.26, Figure 3A). In addition, the
SMD remained significant (−0.30, 95% CI −0.43 to −0.16, p
< 0.001) with a similar between-study variance (I2 = 62.7%, p
< 0.001), after removing the two studies that accounted for a
third of the total participants (17, 18). The Begg’s (p = 0.83)
and Egger’s (p = 0.66) t-tests showed no evidence of publication
bias. Accordingly, the trim-and-fill analysis did not add any study
to the funnel plot (Figure 3B). In meta-regression analysis, age
(t = −0.74, p = 0.47), gender (t = −0.21, p = 0.25), endpoint
(t = −0.92, p = 0.37), study design (t = −0.78, p = 0.45), AST
(t = −1.00, p = 0.34), ALT (t = −1.40, p = 0.19), D-dimer
(t =−2.00, p= 0.10), diabetes (t = 0.43, p= 0.68), hypertension
(t = −1.44, p = 0.17) and cardiovascular disease (t = 0.54,
p = 0.60) were not associated with the SMD. A trend toward
significance was observed with WBC (t =−2.01, p= 0.07), CRP






















TABLE 1 | Characteristics of the studies in COVID-19 patients, according to disease severity or survival status, included in the meta-analysis.






































Chen et al., China
(17)
7 657 62 271/386 3.96 ± 0.84 NR NR 1.18 ± 0.62 173 65 107/66 3.93 ± 0.97 NR NR 1.12 ± 0.68
Chen et al., China
(18)
7 577 63 297/280 3.86 ± 0.81 2.41 ± 0.73 0.93 ± 0.24 1.27 ± 0.51 104 73 65/39 3.51 ± 0.76 2.12 ± 0.72 0.81 ± 0.23 1.38 ± 0.50
Deng et al., China
(19)
7 53 35 24/29 NR NR 1.09 ± 0.43 1.07 ± 0.33 12 33 12/0 NR NR 0.83 ± 0.27 1.39 ± 0.73
Gao et al., China
(20)
5 175 70 79/96 4.03 ± 0.81 NR NR 1.23 ± 0.52 35 74 22/13 3.47 ± 1.04 NR NR 1.37 ± 0.34
Hu et al., China
(21)
6 87 46 42/45 3.74 ± 0.65 1.88 ± 0.59 1.24 ± 0.34 1.27 ± 0.60 27 62 18/9 3.95 ± 0.84 1.88 ± 0.60 1.03 ± 0.24 1.34 ± 0.42
Huang et al., China
(22)
5 2,391 62 1,165/1,226 NR 2.40 ± 0.78 0.96 ± 0.26 1.33 ± 0.59 232 70 161/71 NR 1.96 ± 0.81 0.75 ± 0.27 1.65 ± 0.76
Lei et al., China
(23)
5 50 65 22/28 3.90 ± 0.65 NR NR 1.27 ± 0.47 65 69 36/29 3.93 ± 0.71 NR NR 1.19 ± 0.50
Li et al., China (24) 7 312 49 131/181 3.97 ± 0.85 2.21 ± 0.65 1.06 ± 0.29 1.50 ± 0.89 211 62 119/92 3.83 ± 0.84 2.17 ± 0.66 0.98 ± 0.28 1.53 ± 0.71
Li et al., China (25) 6 45 50 24/21 3.60 ± 0.86 NR NR 1.09 ± 0.58 89 64 51/38 3.62 ± 0.99 NR NR 1.20 ± 0.60
Lv et al., China (26) 6 49 63 24/25 3.85 ± 0.76 2.50 ± 0.70 0.90 ± 0.15 1.25 ± 0.44 45 62 24/21 3.54 ± 0.64 2.13 ± 0.73 0.83 ± 0.23 1.37 ± 0.76
Petrilli et al., USA
(27)
7 1,739 60 1,016/723 NR 1.84 ± 0.75 NR NR 990 68 656/334 NR 1.47 ± 0.69 NR NR
Qin et al., China (7) 7 174 51 91/83 4.04 ± 1.14 2.20 ± 0.91 0.86 ± 0.31 1.10 ± 0.54 74 65 39/35 3.9 ± 1.12 1.99 ± 0.75 1.03 ± 0.49 1.22 ± 0.59
Shu et al., China
(28)
6 207 54 79/128 4.43 ± 0.81 2.33 ± 0.67 1.07 ± 0.22 1.60 ± 0.74 86 65 56/30 3.87 ± 0.74 2.07 ± 0.52 1.03 ± 0.22 1.43 ± 0.51
Sun et al., China
(29)
7 49 52 26/23 4.35 ± 0.94 2.52 ± 0.68 1.20 ± 0.31 1.27 ± 0.73 50 71 34/16 3.63 ± 1.17 2.14 ± 0.81 0.93 ± 0.28 1.09 ± 0.68
Tanaka et al.,
France (30)
6 32 55 21/11 3.27 ± 1.11 1.90 ± 0.74 0.77 ± 0.44 2.13 ± 1.04 16 59 10/6 3.10 ± 1.41 1.60 ± 0.81 0.63 ± 0.30 2.23 ± 0.96
Wang et al., China
(31)
5 72 44 29/43 NR 2.57 ± 0.67 1.10 ± 0.30 NR 71 65 44/27 NR 2.63 ± 0.59 0.87 ± 0.22 NR
Wang et al., China
(32)
7 184 NR NR 3.80 ± 0.81 2.66 ± 0.65 0.82 ± 0.21 1.12 ± 0.50 44 NR NR 3.61 ± 0.82 2.58 ± 0.56 0.74 ± 0.27 1.07 ± 0.44
Wei et al., China (6) 5 394 64 189/205 4.52 ± 1.06 2.34 ± 0.54 1.30 ± 0.33 1.83 ± 0.74 203 69 116/87 4.17 ± 1.16 2.14 ± 0.63 1.24 ± 0.33 1.56 ± 0.82
Xie et al., China
(33)
6 38 61 14/24 4.26 ± 0.83 2.22 ± 0.35 1.32 ± 0.34 1.33 ± 0.76 24 72 13/11 4.24 ± 1.24 2.51 ± 1.19 1.12 ± 0.43 1.34 ± 0.59
Xue et al., China
(34)
7 56 61 30/26 3.97 ± 1.28 2.24 ± 0.81 1.03 ± 0.33 1.48 ± 0.56 58 64 34/24 3.61 ± 0.66 2.09 ± 0.50 0.92 ± 0.30 1.31 ± 0.52
Zhang et al., China
(35)
7 46 61 24/22 3.83 ± 0.67 NR 0.97 ± 0.22 1.37 ± 0.59 52 66 34/18 3.30 ± 0.89 NR 0.77 ± 0.37 1.60 ± 0.81
Zhang et al., China
(36)
6 47 61 18/29 4.57 ± 1.51 2.74 ± 0.85 1.11 ± 0.24 1.58 ± 1.02 27 72 18/9 3.85 ± 1.21 2.29 ± 1.11 0.95 ± 0.34 1.28 ± 0.65
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FIGURE 2 | Forest plot of studies examining total cholesterol concentrations in COVID-19.
(t = −1.94, p = 0.07), albumin (t = −2.31, p = 0.05), and
creatinine (t =−1.94, p= 0.07).
LDL-Cholesterol
Sixteen studies investigated LDL-cholesterol concentrations in
8,670 COVID-19 patients, 6,408 (51% males, mean age 60 years)
with low severity or survivor status and 2,262 (63% males,
mean age 68 years) with high severity or non-survivor status
during follow up (Table 1) (6, 7, 18, 21, 22, 24, 26–34, 36).
Fourteen studies were conducted in China (6, 7, 18, 21, 22, 24,
26, 28, 29, 31–34, 36), one in USA (27), and one in France
(30). Three studies were prospective (27, 29, 30), whilst the
remaining 13 were retrospective (6, 7, 18, 21, 22, 24, 26, 28, 31–
34, 36). Endpoints included disease severity based on current
clinical guidelines in 12 (6, 7, 21, 26–29, 31–34, 36), ICU
admission in one (24), and survival status in three (18, 22, 30).
The overall standardized mean difference in LDL-cholesterol
concentrations between COVID-19 patients with low vs. high
severity or survivor vs. non-survivor status is shown in Figure 4.
In 13 studies, patients with high severity or non-survivor status
had lower LDL-cholesterol concentrations when compared to
those with low severity or survivor status (mean difference range,
−0.56 to −0.06) (6, 7, 18, 22, 24, 26–30, 32, 34, 36), although the
difference was not statistically significant in six studies (7, 24, 30,
32, 34, 36). In three studies (21, 23, 25), LDL-concentrations were
non-significantly lower in patients with low severity or survivor
status (mean difference range 0.10 to 0.37), whereas in one study
no difference was observed between the groups (mean difference
0.00) (21). The pooled results showed that LDL-concentrations
were significantly lower in patients with high severity or non-
survivor status (SMD−0.30, 95% CI−0.41 to−0.18, p < 0.001),
with large heterogeneity between studies (I2 = 71.9%, p< 0.001).
In sensitivity analysis, the pooled SMD values were not altered
when individual studies were in turn omitted (effect size ranged
between−0.33 and−0.27, Figure 5A). In addition, the SMD was
reduced but still significant (−0.24, 95% CI −0.35 to −0.13, p <
0.001), with a reduction in between-study variance (I2 = 47.9%,
p= 0.02), after removing the two studies that accounted for 62%
of all participants (22, 27). The Egger’s (p = 0.02), but not the
Begg’s (p = 0.44), t-test showed the presence of publication bias.
Accordingly, the trim-and-fill method identified seven potential
missing studies to add on the left side of the funnel plot to ensure
symmetry (Figure 5B). The adjusted SMD was further increased
(−0.47, 95% CI −0.35 to −0.60, p < 0.001). In meta-regression
analysis, age (t = 2.37, p = 0.03) and hypertension (t = 2.92,
p = 0.02) were significantly and positively associated with the
SMD. By contrast, non-significant relationships were observed
with gender (t = 0.26, p = 0.80), endpoint (t = 0.11, p = 0.92),
study design (t =−1.58, p= 0.14), country (t =−1.24 p= 0.24),
AST (t = −0.09, p = 0.93), ALT (t = 0.23, p = 0.82), D-dimer
(t = −0.67, p = 0.55), WBC (t = −0.92, p = 0.38), CRP
(t = −0.54, p = 0.60), albumin (t = 0.01, p = 0.99), creatinine
(t = −0.54, p = 0.60), diabetes (t = 1.64, p = 0.14), and
cardiovascular disease (t = 0.67, p= 0.53).
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FIGURE 3 | (A) Sensitivity analysis of the association between total cholesterol and COVID-19. The influence of individual studies on the overall standardized mean
difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CIs). The hollow circles
represent the pooled SMD when the remaining study is omitted from the meta-analysis. The two ends of each broken line represent the 95% CIs. (B) Funnel plot of
studies investigating low vs. high severity or surviving vs. non-surviving status after trimming and filling. Dummy studies and genuine studies are represented by
enclosed circles and free circles, respectively.
HDL-Cholesterol
Seventeen studies assessed HDL-cholesterol concentrations in
6,104 COVID-19 patients, 4,768 (48% males, mean age 60 years)
with low severity or survivor status and 1,336 (62% males, mean
age 67 years) with high severity or non-survivor status during
follow up (Table 1) (6, 7, 18, 19, 21, 22, 24, 26, 28–36). All studies
were performed in China, except one, conducted in France (30).
Two studies were prospective (29, 30), whilst the remaining
15 were retrospective (6, 7, 18, 19, 21, 22, 24, 26, 28, 31–36).
Endpoints included disease severity based on current clinical
guidelines in 12 (6, 7, 19, 21, 26, 28, 29, 31–34, 36), ICU
admission in two (24, 35), and survival status in three (18, 22, 30).
The overall SMD in HDL-cholesterol concentrations between
COVID-19 patients with low vs. high severity or survivor
vs. non-survivor status is reported in Figure 6. In 16 studies,
patients with high severity or non-survivor status had lower
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FIGURE 4 | Forest plot of studies examining LDL-cholesterol concentrations in COVID-19.
HDL-cholesterol concentrations than those with low severity or
survivor status during follow up (mean difference range,−0.91 to
−0.18) (6, 18, 19, 21, 22, 24, 26, 28–36), although the difference
was not statistically significant in four (26, 28, 30, 34). In the
remaining study, HDL-concentrations were significantly lower
in patients with low severity or survivor status during follow
up (mean difference 0.46) (7). The pooled results showed that
HDL-concentrations were significantly lower in patients with
high severity or non-survivor status (SMD −0.44, 95% CI −0.62
to−0.26, p< 0.001), with extreme heterogeneity between studies
(I2 = 83.9%, p < 0.001). Sensitivity analysis showed that the
pooled SMD values were not affected when each study was
in turn omitted (effect size ranged between −0.50 and −0.41,
Figure 7A). In addition, the SMD was reduced though remained
significant (−0.40, 95% CI −0.58 to −0.22, p<0.001), with a
slight reduction in between-study variance (I2 = 76.5%, p <
0.001), after removing two studies accounting for 54% of all
participants (18, 22). The Begg’s (p= 0.39) and Egger’s (p= 0.95)
t-tests showed no evidence of publication bias. Accordingly, the
trim-and-fill method did not add any study to the funnel plot
(Figure 7B). Inmeta-regression analysis, age (t= 0.61, p= 0.55),
gender (t = −1.52, p = 0.15), endpoint (t = −0.86, p = 0.40),
study design (t = −0.89, p = 0.39), AST (t = −0.73, p = 0.48),
ALT (t = −0.41, p = 0.61), D-dimer (t = −1.32, p = 0.26),
WBC (t = −1.63, p = 0.13), albumin (t = 1.67, p = 0.15),
diabetes (t=−0.57, p= 0.58), cardiovascular disease (t=−0.87,
p = 0.41) and hypertension (t = −0.95, p = 0.37), were not
significantly associated with SMD. A trend toward statistical
significance was observed with CRP (t = −2.03, p = 0.07) and
creatinine (t =−2.03, p= 0.07).
Triglycerides
Twenty studies reported triglyceride concentrations in 7,250
COVID-19 patients, 5,623 (47% males, mean age 60 years) with
low severity or survivor status and 1,627 (61%males, mean age 67
years) with high severity or non-survivor status during follow up
(Table 1) (6, 7, 17–26, 28–30, 32–36). All studies were performed
in China, except one, conducted in France (30). Two studies
were prospective (29, 30), whilst 18 were retrospective (6, 7, 17–
26, 28, 32–36). Endpoints included disease severity based on
current clinical guidelines in 14 studies (6, 7, 17, 19, 21, 23, 25, 26,
28, 29, 32–34, 36), ICU admission in two (24, 35), and survival
status in four (18, 20, 22, 30). The overall SMD in triglyceride
concentrations between patients with low vs. high severity or
survivor vs. non-survivor status is reported in Figure 8. In
eight studies, patients with high severity or non-survivor status
had lower triglyceride concentrations when compared to those
with low severity or survivor status during follow up (mean
difference range, −0.35 to −0.09) (6, 17, 23, 28, 29, 32, 34, 36),
although the difference was statistically significant only in one
study (6). In 12 studies (7, 18–22, 24–27, 30, 33, 35), triglyceride
concentrations were lower in patients with low severity or
survivor status (mean difference range, 0.04 to 0.75), although the
difference was statistically significant only in three studies (18, 19,
22). The pooled results showed that triglyceride concentrations
were similar in the two groups (SMD 0.04, 95% CI −0.10 to
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FIGURE 5 | (A) Sensitivity analysis of the association between LDL-cholesterol and COVID-19. The influence of individual studies on the overall standardized mean
difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CIs). The hollow circles
represent the pooled SMD when the remaining study is omitted from the meta-analysis. The two ends of each broken line represent the 95% CIs. (B) Funnel plot of
studies investigating low vs. high severity or surviving vs. non-surviving status after trimming and filling. Dummy studies and genuine studies are represented by
enclosed circles and free circles, respectively.
−0.19, p = 0.57), with extreme heterogeneity between studies
(I2 = 81.0%, p < 0.001). Sensitivity analysis showed that the
pooled SMD values were not altered when each study was in turn
removed (effect size ranged between 0.00 and 0.07, Figure 9A).
In addition, the SMD remained non-significant (0.10, 95% CI
−0.12 to 0.14, p = 0.88), but with a reduction in between-study
variance (I2 = 62.8%, p < 0.001), after removing two studies
that accounted for 48% of all participants (17, 22). The Begg’s
(p = 0.67) and Egger’s (p = 0.58) t-tests showed no evidence of
publication bias. Accordingly, the trim-and-fill method did not
add any study to the funnel plot (Figure 9B). Meta-regression
analysis showed that endpoint (t = 3.29, p = 0.004) and AST (t
=2.65, p = 0.02) were significantly associated to the effect size,
with a trend toward significance for albumin (t = 2.08, p= 0.07).
By contrast, age (t=−0.50, p= 0.62), gender (t= 0.44, p= 0.66),
study design (t = −0.68, p = 0.51), ALT (t = 0.94, p = 0.36),
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FIGURE 6 | Forest plot of studies examining HDL-cholesterol concentrations in COVID-19.
D-dimer (t = −0.44, p = 0.65), WBC (t = 1.72, p = 0.11), CRP
(t = −0.15, p = 0.88), creatinine (t = −0.15, p = 0.88), diabetes
(t = 0.38, p= 0.71), cardiovascular disease (t =−1.06, p= 0.32)
and hypertension (t = −0.36, p = 0.73) were not significantly
associated with the SMD.
DISCUSSION
In our systematic review and meta-analysis, the serum/plasma
concentrations of total cholesterol, LDL-cholesterol, and HDL-
cholesterol were significantly lower in COVID-19 patients with
more severe disease, ascertained clinically or with documented
transfer to ICU, and in those who did not survive during follow
up when compared to patients with milder forms of the disease
or who survived during follow up. By contrast, no significant
associations were observed between triglyceride concentrations,
COVID-19 severity, and mortality. The observed SMD values for
total cholesterol, LDL-cholesterol, and HDL-cholesterol, −0.29,
−0.30, and −0.44, respectively, indicate an effect size that is
likely to be of biological and/or clinical relevance (37). The
heterogeneity between studies was generally large-to-extreme
however in sensitivity analysis the effect size of different lipid
fractions was not significantly affected when each study was in
turn removed. Further analyses based on the Begg’s and Egger’s
t-tests did not show evidence of significant publication bias,
except for LDL-cholesterol. With this lipid fraction, the trim-
and-fill method identified seven potential missing studies to add
on the left side of the funnel plot to ensure symmetry. In meta-
regression analysis, performed to identify specific study, clinical
and demographic factors potentially associated with the SMD,
only age and hypertension were significantly associated with the
SMD for LDL whereas the type of study endpoint and AST values
were significantly associated with the SMD for triglycerides.
The exact mechanisms responsible for the lower
plasma/serum concentrations of total cholesterol, LDL-
cholesterol, and HDL-cholesterol in patients with COVID-19,
particularly in those with the more severe forms of the disease,
are unclear. A reduction in cholesterol fractions has been
previously reported with other viral agents, particularly the
Human Immunodeficiency Virus-1 (HIV-1). In patients with
HIV-1 infection, a significant reduction in plasma/serum
concentrations of HDL-cholesterol has been linked with the
impaired function of the ATP-binding cassette transporter
A1-dependent cholesterol efflux in macrophages and the
activation of endothelial lipase and phospholipase A2, mediated
by a pro-inflammatory state (38–40). While alterations in
these transporters and enzymes have not been specifically
reported in patients with COVID-19, other mechanisms may
be involved in this group. For example, it has been speculated
that the increased utilization of cholesterol for the synthesis
of pulmonary surfactant, as a response to viral infection and
replication in the lungs, and/or a poor nutritional status
associated with reduced liver synthetic capacity, might account,
at least in part, for the observed hypocholesterolemia in severe
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FIGURE 7 | (A) Sensitivity analysis of the association between HDL-cholesterol and COVID-19. The influence of individual studies on the overall standardized mean
difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CIs). The hollow circles
represent the pooled SMD when the remaining study is omitted from the meta-analysis. The two ends of each broken line represent the 95% CIs. (B) Funnel plot of
studies investigating low vs. high severity or surviving vs. non-surviving status after trimming and filling. Dummy studies and genuine studies are represented by
enclosed circles and free circles, respectively.
COVID-19 (7). The latter hypothesis is supported by the results
of a recent systematic review and meta-analysis which reported
that lower concentrations of serum prealbumin, a combined
marker of malnutrition and inflammation, are also significantly
associated with higher COVID-19 severity and adverse clinical
outcomes (41). It is also possible that the non-specific presence
of sepsis, similar to other bacterial and viral infections, can lead
to the observed alterations in lipid profile through the activation
of specific pro-inflammatory cytokines and/or the increased
expression of the scavenger receptor class B type 1 (6, 42). While
previous studies have reported an inverse association between
CRP and HDL-cholesterol concentrations in COVID-19, the
results of our meta-regression analysis showed a non-significant
trend for an association between the SMD for HDL-cholesterol
and CRP (t=−2.03, p= 0.07). Further experimental and human
studies are required to clarify whether the association between
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FIGURE 8 | Forest plot of studies examining the concentrations of triglycerides in COVID-19.
an excessive inflammatory state and HDL-cholesterol, and other
lipid fractions, in patients with severe COVID-19 is mediated
by non-specific inflammatory markers or individual cytokines.
The significant differences observed in total-cholesterol, HDL-
cholesterol, and LDL-cholesterol concentrations between
COVID-19 patients with different severity and clinical outcomes
could also be theoretically amplified, at least in part, by the
different pre-admission and/or hospital use of cholesterol
lowering agents, particularly statins, in these subgroups.
However, a systematic review and meta-analysis of European
and North American studies in 2,398 patients with COVID-19
has recently reported that the use of statins was associated with
a significantly reduced risk of disease progression or mortality
(odds ratio, OR, 0.59, 95% CI 0.35 to 0.99, p = 0.02). This trend
persisted after excluding studies where statins were commenced
during hospital admission (OR 0.51, 95% CI 0.41 to 0.64, p-value
not reported) (43). Pending confirmation in other ethnic groups,
for example, Chinese patients, these results suggest the presence
of a complex interplay between lipid profile on admission,
pre-hospital and in-hospital statin use, disease severity and
mortality in COVID-19. The limited information available on
the use of statins in the studies identified in our systematic review
prevented the conduct of meta-regression analysis to investigate
associations between statin use and the SMD of various lipid
fractions. This important issue requires further research as the
results of in vitro experiments support the presence of anti-viral
effects of statins against SARS-CoV-2 (44).
The large-to-extreme between-study heterogeneity represents
a potential limitation in our study. However, there was no
evidence of publication bias, barring studies reporting LDL-
cholesterol concentrations, and the overall effect size was not
significantly influenced in sensitivity analyses. The lack of
significant associations between study, clinical, and demographic
characteristics and the SMD, barring the associations between age
and hypertension and the SMD for LDL and between the type of
study design and AST and the SMD for triglycerides previously
described, suggest that other unreported factors, for example,
statin use and/or issues with standardization of the analytical
methods for the measurement of different lipid fractions (45),
might contribute to the observed heterogeneity. An additional
limitation in our study was the lack of information provided in
most studies regarding the exact timing of the blood collection for
lipid profile, for example, on the day of admission or thereafter.
In conclusion, our systematic review and meta-analysis
has shown that lower plasma/serum concentrations of total
cholesterol, LDL-cholesterol, and HDL-cholesterol, but not
triglycerides, are significantly associated with more severe disease
and increased mortality in patients with COVID-19. While
the assessment of lipid profile, with or without other patient
characteristics, might assist with risk stratification, additional
prospective studies are required to investigate the relationship
between various cholesterol fractions and statin use, the temporal
variations in lipid concentrations, and the clinical impact of these
variables in this patient group.
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FIGURE 9 | (A) Sensitivity analysis of the association between serum triglycerides and COVID-19. The influence of individual studies on the overall standardized mean
difference (SMD) is shown. The middle vertical axis indicates the overall SMD and the two vertical axes indicate the 95% confidence intervals (CIs). The hollow circles
represent the pooled SMD when the remaining study is omitted from the meta-analysis. Two ends of each broken line represent the 95% CIs. (B) Funnel plot of
studies investigating low vs. high severity or surviving vs. non-surviving status after trimming and filling. Dummy studies and genuine studies are represented by
enclosed circles and free circles, respectively.
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